Xiaohui He
YOU?
Author Swipe
View article: Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Epigenetically conferred ring-stage survival in Plasmodium falciparum against artemisinin treatment
Epigenetically conferred ring-stage survival in Plasmodium falciparum against artemisinin treatment Open
Artemisinin and its semisynthetic derivatives (ART) are crucial medicines in artemisinin-based combination therapies worldwide. Despite ART's efficacy, small proportions of young intraerythrocytic ring stage parasites can survive the drug'…
View article: Enhancing treatment adherence in dialysis patients through digital health interventions: a systematic review and meta-analysis of randomized controlled trials
Enhancing treatment adherence in dialysis patients through digital health interventions: a systematic review and meta-analysis of randomized controlled trials Open
Digital health interventions effectively enhance multiple dimensions of treatment adherence in dialysis patients, underscoring their value for incorporation into routine clinical practice.
View article: ParSite is a multicolor DNA labeling system that allows for simultaneous imaging of triple genomic loci in living cells
ParSite is a multicolor DNA labeling system that allows for simultaneous imaging of triple genomic loci in living cells Open
The organization of the human genome in space and time is critical for transcriptional regulation and cell fate determination. However, robust methods for tracking genome organization or genomic interactions over time in living cells are l…
View article: <i>Oviductus Ranae</i> Promotes Follicle Growth Through the <scp>PI3K</scp>/<scp>AKT</scp> Signaling Pathway In Vivo and In Vitro in Rat
<i>Oviductus Ranae</i> Promotes Follicle Growth Through the <span>PI3K</span>/<span>AKT</span> Signaling Pathway In Vivo and In Vitro in Rat Open
The development status of follicles determines the menstrual cycle and estrogen levels, which is crucial to women's health. Oviductus Ranae is a natural product for both medicine and food, which has “estrogenic effect”. However, few studie…
View article: Up-Regulated MiR-616-5p Promotes the Progression of Nasopharynx Cancer through GSK3<i>β</i>
Up-Regulated MiR-616-5p Promotes the Progression of Nasopharynx Cancer through GSK3<i>β</i> Open
Nasopharyngeal carcinoma (NPC) is a serious malignancy occurring in nasopharynx with high incidence, which is caused by excessive proliferation of nasopharyngeal cells. It has been reported that both microRNA (miR)-616-5p and glycogen synt…
View article: Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer Open
Supplementary Tables
View article: Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer Open
Supplementary Tables
View article: Data from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Data from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer Open
Purpose: The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyr…
View article: Tracking pairwise genomic loci by the ParB–ParS and Noc-NBS systems in living cells
Tracking pairwise genomic loci by the ParB–ParS and Noc-NBS systems in living cells Open
The dynamics of genomic loci pairs and their interactions are essential for transcriptional regulation and genome organization. However, a robust method for tracking pairwise genomic loci in living cells is lacking. Here we developed a mul…
View article: Genetic landscape and prognostic value of IRF4 alterations in Diffuse large B-cell lymphoma patients
Genetic landscape and prognostic value of IRF4 alterations in Diffuse large B-cell lymphoma patients Open
Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell NHL with high heterogeneity. Patients with IRF4 alterations in various hematologic malignancies have a different prognosis. Methods: From January 1 st , 2006 to Dec…
View article: Multi-Omics Analysis of Tislelizumab Plus Nab-Paclitaxel and Cisplatin as Neoadjuvant Immunochemotherapy for Locally Advanced Hypopharyngeal Squamous Cell Carcinoma: A Prospective Single-Arm Phase 2 Trial
Multi-Omics Analysis of Tislelizumab Plus Nab-Paclitaxel and Cisplatin as Neoadjuvant Immunochemotherapy for Locally Advanced Hypopharyngeal Squamous Cell Carcinoma: A Prospective Single-Arm Phase 2 Trial Open
View article: Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma Open
Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is the current standard of care for the first-line treatment of recurrent or metastatic N…
View article: 929P Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with with recurrent/ metastatic head and neck squamous-cell carcinoma (R/M SCC) of the nasal cavity and paranasal sinuses
929P Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with with recurrent/ metastatic head and neck squamous-cell carcinoma (R/M SCC) of the nasal cavity and paranasal sinuses Open
View article: Obesity and head and neck cancer risk: a mendelian randomization study
Obesity and head and neck cancer risk: a mendelian randomization study Open
View article: Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Supplementary Tables
View article: Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Purpose:The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyro…
View article: Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Supplementary Tables
View article: Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas Open
Background This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs). Methods In t…
View article: Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Purpose:The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyro…
View article: Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Supplementary Tables
View article: Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.
View article: Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Supplementary Tables
View article: Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer Open
Purpose:The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyro…
View article: Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients Open
Background Patients with relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL) have poor outcomes and few treatment options. We report the preliminary results of the efficacy and safety of PD‐1 monoclonal antibody (mab) plus Rituxi…